Navigation Links
Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
Date:2/5/2009

MELBOURNE, Australia, Feb.5 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has successfully concluded dose-escalation in its oral Phase I study for CYT997, the company's anticancer vascular-disrupting agent (VDA).

The primary objectives of this safety and tolerability study have been achieved. These were to determine the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) for the agent when administered orally in capsule form every two weeks to patients with a diverse range of solid tumors. Safety and tolerability data from this study augments data obtained in the company's first Phase I study where CYT997 was administered intravenously. Together, these studies suggest that the CYT997 is a potent and selective VDA which is well tolerated at biologically efficacious doses and is worthy of further investigation as a novel anticancer agent.

"Cytopia has now demonstrated the broad clinical potential of CYT997 in both intravenous and oral forms," said Mr. Andrew Macdonald, CEO. "The oral activity of CYT997 is a key advantage over most other vascular disrupting agents which are administered intravenously. The oral activity of the agent should markedly improve its clinical and commercial value."

The company has already commenced Phase II studies for the intravenous form of CYT997 and intends to undertake similar efficacy studies for the oral presentation. Investigating the safety and efficacy of metronomic dosing, frequent oral administration at a comparatively low, but biologically effective dose, is of particular interest.

This oral trial was partly funded under the company's $A3 million Commercial Ready grant.

Preliminary trial data

CYT997 was generally well tolerated in this study with a maximum tolerated dose in cancer patients of ca 165 mg/m2. This dose resulted in maximal plasma concentrations some twofold higher than those obse
'/>"/>

SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytopia Scientific Presentations on JAK2 Inhibitor Program
2. Cytopia Commences Second Phase II Study in Brain Cancer
3. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
4. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
5. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
6. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
7. Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
8. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
9. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
10. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
11. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... MUMBAI, India , September 17, 2014 ... TRPA1 antagonist, GRC 17536, has shown positive data in ... with painful diabetic neuropathy , ... Transient Receptor Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 ... blind, placebo controlled, multi-centre, proof of concept study conducted ...
(Date:9/17/2014)... Texas , Sept. 17, 2014  Lightbeam ... Direct Accountable Care Organization (Physician Direct ACO) to ... their physicians in providing better care while reducing ... Physician Direct Accountable Care Organization ... Network Services (OPNS). The OPNS mission is to ...
(Date:9/17/2014)... 2014 According to a new ... Battery, Memory Device, Display, & Microprocessor/MCU), by Application (Imaging, ... by Geography - Global Forecast to 2020", published by ... expected to reach $56.50 Billion by 2020, growing at ... Browse 235 market data Tables and 71 Figures ...
Breaking Medicine Technology:Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 North ... were recently granted several awards for their top-notch services. ... patient experience, orthopedic care and GYN surgery. , Hospital-wide, ... Safety Excellence Award™. They have received this award for ... among the top 5 percent in the nation for ...
(Date:9/17/2014)... News) -- A blood test that measures DNA from ... better assessment of the state of a man,s disease, ... this blood test could reveal when treatment for ... tumor growth, the researchers suggested. "Our study showed ... prostate cancer and often initially very effective started to ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Wright ... Conserve line of metal-on-metal hip replacements continue to ... U.S. District Court, Northern District of Georgia, Bernstein ... List issued by the U.S. Judicial Panel on ... 397 product liability claims have been filed in ...
(Date:9/17/2014)... are Asian Americans at higher risk of developing type ... the disease at lower body weights? One part of ... high-fiber, low-fat Asian diets to current westernized diets, which ... says George King, M.D., Senior Vice President and Chief ... author of the study. , A Joslin randomized clinical ...
(Date:9/17/2014)... London, UK (PRWEB) September 17, 2014 ... of the total medical technology market, focusing on molecular ... cancer, chronic diseases, and genetic testing. The IVD market ... billion by the end of 2017. The major drivers ... testing; need for speed, which is evidenced by the ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... study of its kind, scientists from Toronto,s Centre for Addiction and ... a higher risk of developing schizophrenia. This finding was based on ... to a group that did not use drugs, but also to ... published online on Nov. 8, 2011, at AJP in ...
... University of Colorado Denver announced today that it will ... by the Bill & Melinda Gates Foundation that enables ... health and development challenges. Assistant Professor Zhiyong (Jason) ... Applied Science will pursue an innovative global health research ...
... (November 7, 2011) AMRI (NASDAQ: AMRI) announced today ... Eli Lilly and Company, it anticipates hiring more than ... to support Lilly,s drug discovery programs. The chemists will ... they will support the medicinal chemistry department. This ...
... -- ,Neuromuscular warm-ups may reduce knee injuries among female ... neuromuscular warm-up, an athlete begins with easy cardiovascular exercise ... in the sport. The study included 90 ... from public schools in Chicago. Half the coaches were ...
... have been going electronic, and patients, caregivers, and ... digital world of health information. Now three institutions ... populationpeople with disabilitiescan best access this information. ... Inglis Foundation, also based in Philadelphia, are partnering ...
... Hopkins Center for Injury Research and Policy finds fire ... comprehensive and coordinated approach to fire prevention. The study, ... fire service, highlights the diversity of prevention initiatives underway ... a sense of community are keys to success for ...
Cached Medicine News:Health News:CAMH study suggests increased risk of schizophrenia in heavy methamphetamine users 2Health News:Specialized Warm-Up May Reduce Girls' Knee Injuries 2Health News:Grant will help bridge digital divide for people with disabilities 2Health News:Grant will help bridge digital divide for people with disabilities 3Health News:Delaware Fire Service offers important lessons for fire prevention programs nationwide 2
... 6000 lets you manually ... precise positioning. The superior ... immediate and exact positioning ... making it especially effective ...
The Total Toe System offers a new generation in first metatarsophalangeal joint reconstruction....
The Acumed Great Toe System is a two-piece non-constrained implant for the first MP joint. The system was developed to provide ease of use for the surgeon, combined with precise instrumentation and a...
The design features of the Mini Lag Screw System simplify the screw fixation by reducing possible sources of error, reducing instrumentation, and decreasing the time of fixation....
Medicine Products: